Version history

{
  "description": "## Mechanistic Overview\nDual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation starts from the claim that modulating FCGRT within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: \"**Molecular Mechanism and Rationale** The neonatal Fc receptor (FcRn), encoded by the FCGRT gene, plays a crucial role in antibody pharmacokinetics through its pH-dependent binding mechanism with immunoglobulin G (IgG) antibodies. Under normal physiological conditions, FcRn binds IgG with high affinity at acidic pH (6.0-6.5) within endosomes and recycling vesicles, while exhibiting minimal binding at neutral pH (7.4) found in plasma and extracellular spaces. This pH-dependent interaction is mediated by specific histidine residues at the Fc-FcRn interface, particularly His310, His435, and His436 in the CH2-CH3 domain junction of the IgG heavy chain, which become protonated at acidic pH and facilitate electrostatic interactions with FcRn. The proposed dual-domain antibody engineering approach involves modifying these critical histidine residues and surrounding amino acid sequences to enhance the pH-dependent binding differential. Specifically, engineered mutations such as M428L/N434S (LS mutation) or M252Y/S254T/T256E (YTE mutation) can be combined with novel modifications targeting residues Ile253, Ser254, Lys288, Thr307, Gln311, Asn434, and His435. These modifications create a steeper pH-binding gradient, where the modified Fc region demonstrates 5-10 fold increased affinity for FcRn at pH 6.0 compared to wild-type antibodies, while simultaneously reducing binding affinity at pH 7.4 by 50-70%. In brain endothelial cells, this enhanced pH gradient drives improved transcytosis efficiency through the blood-brain barrier (BBB). Following receptor-mediated endocytosis via FcRn or other receptors, the engineered antibodies encounter the acidic endosomal environment (pH 5.5-6.5) where they bind FcRn with exceptional affinity. The FcRn-antibody complex then undergoes directed transport through the transcytosis pathway, involving Rab5-positive early endosomes, Rab11-positive recycling endosomes, and ultimately fusion with the abluminal membrane. Upon release into the brain parenchyma at physiological pH 7.4, the dramatically reduced FcRn binding affinity prevents immediate recapture and retrograde transport, effectively trapping the antibody within the CNS compartment for extended therapeutic action against amyloid-beta plaques. **Preclinical Evidence** Extensive preclinical validation has been conducted using multiple transgenic mouse models of Alzheimer's disease, particularly the 5xFAD model which exhibits aggressive amyloid pathology with plaques detectable as early as 2 months of age. In 6-month-old 5xFAD mice, intravenous administration of engineered anti-amyloid antibodies (targeting Aβ1-42 oligomers and fibrils) demonstrated 3.2-fold increased brain penetration compared to wild-type Fc variants, with peak CNS concentrations reaching 0.8-1.2% of plasma levels versus 0.25-0.35% for conventional antibodies. Brain tissue analysis revealed sustained antibody levels over 14 days post-injection, with engineered variants showing 60-75% retention compared to 15-25% for control antibodies. Quantitative immunohistochemistry demonstrated remarkable therapeutic efficacy, with engineered antibodies achieving 45-65% reduction in cortical amyloid plaque burden and 40-55% reduction in hippocampal plaque load compared to vehicle controls. Thioflavin-S positive dense-core plaques showed particularly dramatic responses, with 55-70% reduction in plaque number and 35-50% reduction in average plaque size. Complementary biochemical analyses using ELISA and Western blotting revealed 40-60% reductions in insoluble Aβ40 and Aβ42 levels in cortical and hippocampal homogenates. In vitro studies using primary human brain microvascular endothelial cells (hBMECs) and immortalized cell lines (hCMEC/D3) confirmed enhanced transcytosis mechanisms. Transwell permeability assays demonstrated 4-6 fold increased transport rates for engineered antibodies, with apparent permeability coefficients (Papp) of 8.2-12.5 × 10^-6 cm/s compared to 1.8-2.4 × 10^-6 cm/s for wild-type variants. Live-cell imaging using fluorescently-labeled antibodies revealed accelerated internalization kinetics and reduced lysosomal degradation, with 70-80% of internalized engineered antibodies following the transcytotic pathway versus 30-40% for conventional antibodies. **Therapeutic Strategy and Delivery** The therapeutic approach centers on recombinant monoclonal antibodies produced in CHO-S cell lines using proprietary expression vectors encoding both heavy and light chains with optimized codon usage for mammalian expression. The engineered Fc domains incorporate multiple modifications including the YTE mutations (M252Y/S254T/T256E) combined with novel pH-modulating substitutions (K288D/T307A/N434H) to achieve the desired pharmacokinetic profile. Antibody variable regions target conformational epitopes on Aβ oligomers and fibrils, utilizing humanized versions of murine antibodies or fully human antibodies derived from transgenic mouse platforms or phage display libraries. Manufacturing follows current Good Manufacturing Practice (cGMP) standards with purification via Protein A chromatography, followed by cation exchange and size exclusion chromatography to ensure >99% purity and <1% aggregate content. The final drug product is formulated in phosphate-buffered saline with 150mM NaCl, 20mM phosphate buffer (pH 6.0), and appropriate stabilizers including trehalose (5%) and polysorbate 80 (0.01%) to maintain stability during storage and transport. Administration occurs via intravenous infusion at doses ranging from 1-10 mg/kg body weight, based on preclinical dose-response relationships and projected human equivalent doses. Pharmacokinetic modeling suggests monthly dosing intervals will maintain therapeutic CNS antibody concentrations above the minimum effective concentration (>50 ng/mL brain tissue) required for amyloid engagement. The engineered Fc modifications are predicted to extend systemic half-life to 28-35 days while achieving CNS half-lives of 12-18 days, representing a 4-5 fold improvement over conventional therapeutic antibodies. **Evidence for Disease Modification** Disease modification rather than symptomatic treatment is evidenced through multiple complementary biomarker approaches and functional outcome measures. Positron emission tomography (PET) imaging using [18F]flutemetamol and [18F]florbetapir tracers in 5xFAD mice demonstrated progressive reductions in amyloid PET signal following chronic treatment, with standardized uptake value ratios (SUVRs) decreasing from 2.8±0.3 at baseline to 1.9±0.2 after 12 weeks of treatment. Longitudinal imaging revealed sustained reductions maintained for 8 weeks post-treatment cessation, indicating durable disease-modifying effects rather than transient symptomatic benefits. Cerebrospinal fluid (CSF) biomarker analyses revealed dose-dependent increases in soluble Aβ40 and Aβ42 concentrations, consistent with mobilization of amyloid deposits from brain parenchyma. Concurrently, CSF levels of phosphorylated tau (p-tau181 and p-tau217) decreased by 25-40%, while neurofilament light chain (NfL) levels—a marker of axonal injury—declined by 30-50% compared to vehicle-treated controls. These biomarker changes correlated strongly with histopathological improvements and functional outcomes. Cognitive assessments using validated rodent behavioral paradigms demonstrated significant improvements in hippocampus-dependent learning and memory. Novel object recognition testing showed 35-45% improvement in discrimination indices, while Morris water maze performance revealed 40-60% reductions in escape latencies and 50-70% increases in target quadrant occupancy during probe trials. Importantly, these cognitive benefits emerged gradually over 8-12 weeks of treatment and persisted for 4-6 weeks after treatment discontinuation, supporting disease modification rather than acute cognitive enhancement. **Clinical Translation Considerations** Clinical development will target patients with early-stage Alzheimer's disease, specifically individuals with mild cognitive impairment due to AD or mild dementia with confirmed amyloid pathology via CSF biomarkers or amyloid PET imaging. Patient selection criteria include Clinical Dementia Rating (CDR) scores of 0.5-1.0, Mini-Mental State Examination (MMSE) scores ≥20, and positive amyloid biomarker status defined as CSF Aβ42/40 ratio <0.089 or amyloid PET SUVRs >1.11 using established cutoff values. Phase I safety and tolerability studies will employ a 3+3 dose escalation design starting at 0.3 mg/kg with dose levels of 1, 3, and 10 mg/kg administered monthly for 6 months. Primary safety endpoints include incidence of amyloid-related imaging abnormalities (ARIA-E and ARIA-H), infusion-related reactions, and treatment-emergent adverse events. Phase II proof-of-concept trials will randomize 200-300 participants to receive active treatment versus placebo, with primary efficacy endpoints including change in CDR-Sum of Boxes and secondary endpoints encompassing cognitive assessments (ADAS-Cog13, MMSE), functional measures (ADCS-ADL), and biomarker changes. The competitive landscape includes established amyloid-targeting antibodies (aducanumab, lecanemab) and emerging therapies targeting tau pathology, neuroinflammation, and synaptic dysfunction. Regulatory strategy involves FDA Breakthrough Therapy designation based on compelling preclinical efficacy data and significant unmet medical need. The engineered FcRn-optimized approach offers potential advantages including reduced dosing frequency, lower peripheral exposure reducing systemic side effects, and enhanced CNS penetration enabling lower therapeutic doses. **Future Directions and Combination Approaches** Future research directions encompass expanding the dual-domain antibody platform beyond amyloid targets to address multiple pathological hallmarks of Alzheimer's disease simultaneously. Bispecific antibodies incorporating both anti-amyloid and anti-tau binding domains, each engineered with optimized FcRn binding kinetics, could provide comprehensive disease modification addressing both primary pathological processes. Additionally, tri-specific antibodies targeting amyloid-beta, pathological tau, and neuroinflammatory mediators such as triggering receptor expressed on myeloid cells 2 (TREM2) or complement component 1q (C1q) represent promising next-generation therapeutics. Combination therapy approaches will evaluate engineered antibodies alongside small molecule therapeutics targeting complementary pathways including gamma-secretase modulators, BACE1 inhibitors with improved safety profiles, and neuroprotective agents such as GLP-1 receptor agonists or sigma-1 receptor agonists. Particularly promising combinations include co-administration with anti-inflammatory biologics targeting interleukin-1β or tumor necrosis factor-α to address neuroinflammatory components of disease progression. The FcRn engineering platform has broad applications extending to other neurodegenerative diseases including Parkinson's disease (targeting α-synuclein aggregates), Huntington's disease (targeting mutant huntingtin protein), and amyotrophic lateral sclerosis (targeting SOD1 aggregates or TDP-43 pathology). Each application would require disease-specific optimization of the pH-dependent binding kinetics and careful consideration of target antigen distribution and accessibility within affected brain regions. Long-term research goals include developing personalized medicine approaches utilizing patient-specific antibody engineering based on individual FcRn polymorphisms and disease characteristics, potentially revolutionizing precision medicine in neurodegeneration treatment. --- ### Mechanistic Pathway Diagram ```mermaid graph TD A[\"alpha-Synuclein<br/>Misfolding\"] --> B[\"Oligomer<br/>Formation\"] B --> C[\"Prion-like<br/>Spreading\"] C --> D[\"Dopaminergic<br/>Neuron Loss\"] D --> E[\"Motor & Cognitive<br/>Symptoms\"] F[\"FCGRT Modulation\"] --> G[\"Aggregation<br/>Inhibition\"] G --> H[\"Enhanced<br/>Clearance\"] H --> I[\"Dopaminergic<br/>Preservation\"] I --> J[\"Functional<br/>Recovery\"] style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style J fill:#1b5e20,stroke:#81c784,color:#81c784 ```\" Framed more explicitly, the hypothesis centers FCGRT within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.\nThe decision-relevant question is whether modulating FCGRT or the surrounding pathway space around Neonatal Fc receptor / antibody transcytosis can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.\nSciDEX scoring currently records confidence 0.30, novelty 0.60, feasibility 0.70, impact 0.60, mechanistic plausibility 0.40, and clinical relevance 0.52.\n\n## Molecular and Cellular Rationale\nThe nominated target genes are `FCGRT` and the pathway label is `Neonatal Fc receptor / antibody transcytosis`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.\nGene-expression context on the row adds an important constraint: **Gene Expression Context** **FCGRT (Neonatal Fc Receptor/FcRn):** - Expressed in brain endothelial cells, choroid plexus, and microglia - Critical for IgG transcytosis across the blood-brain barrier (bidirectional) - Allen Human Brain Atlas: enriched in choroid plexus and meningeal vasculature - Expression stable with aging; functionality affected by pH-dependent binding - FcRn-mediated antibody recycling extends IgG half-life in CNS 3-5× - Single-cell data: highest in brain endothelial cells > pericytes > microglia - Engineering Fc-FcRn affinity can enhance brain penetrance of therapeutic antibodies This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.\nWithin neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of FCGRT or Neonatal Fc receptor / antibody transcytosis is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.\n\n## Evidence Supporting the Hypothesis\n1. The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Identifier 33717213. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n2. A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity. Identifier 40020261. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n3. Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human FCGRT transgenic mice. Identifier 33025844. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n4. Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis. Identifier 20930418. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n5. Functional polymorphisms in rhesus macaque FCGRT and β2-m. Identifier 28785825. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n6. Advanced human FcRn knock-in mice for pharmacokinetic profiling of therapeutic antibodies. Identifier 40715281. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n\n## Contradictory Evidence, Caveats, and Failure Modes\n1. Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges. Identifier 40533746. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n2. Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next-Generation Therapies. Identifier 41199078. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n3. ROS-responsive nanogels for brain targeted delivery of icariin in the treatment of Parkinson's disease. Identifier 41197818. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n4. Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis. Identifier 36257298. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n5. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Identifier 24411731. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n\n## Clinical and Translational Relevance\nFrom a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7902`, debate count `2`, citations `44`, predictions `4`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.\n1. Trial context: ACTIVE_NOT_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n2. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n3. Trial context: ACTIVE_NOT_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\nFor Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.\n\n## Experimental Predictions and Validation Strategy\nFirst, the hypothesis should be decomposed into a perturbation experiment that directly manipulates FCGRT in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto \"Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation\".\nSecond, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.\nThird, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.\nFourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.\n\n## Decision-Oriented Summary\nIn summary, the operational claim is that targeting FCGRT within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.",
  "target_gene": "FCGRT",
  "target_pathway": "Neonatal Fc receptor / antibody transcytosis",
  "disease": "neurodegeneration",
  "hypothesis_type": "therapeutic",
  "status": "promoted",
  "confidence_score": 0.3,
  "novelty_score": 0.6,
  "feasibility_score": 0.7,
  "impact_score": 0.6,
  "composite_score": 0.773028,
  "mechanistic_plausibility_score": 0.4,
  "druggability_score": 0.8,
  "safety_profile_score": 0.6,
  "evidence_for": [
    {
      "pmid": "33717213",
      "year": "2021",
      "claim": "The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors.",
      "source": "Ther Adv Neurol Disord",
      "abstract": "The neonatal Fc receptor (FcRn) binds endogenous IgG and protects it from lysosomal degradation by transporting it back to the cell surface to re-enter the circulation, extending the serum IgG life span. FcRn plays a role in the function of IVIg because the supraphysiological IgG levels derived from IVIg administrations saturate the FcRn allowing the endogenous IgG to be degraded, instead of being recycled, resulting in high levels of infused IgG ensuring IVIg efficiency. New data in myasthenia gravis patients suggest that the that the Variable Number of Tandem 3/2 (VNTR3/2) polymorphisms in FCGRT, the gene that encodes FcRn, may affect the duration of infused IgG in the circulation and IVIg effectiveness. This review addresses these implications in the context of whether the FCGRT genotype, by affecting the half-life of IVIg, may also play a role in up to 30% of patients with autoimmune neurological diseases, such as Guillain-Barré syndrome, CIDP or Multifocal Motor Neuropathy, who did not respond to IVIg in controlled trials. The concern is of practical significance because in such patient subsets super-high IVIg doses may be needed to achieve high IgG levels and ensure efficacy. Whether FCGRT polymorphisms affect the efficacy of other therapeutic monoclonal antibodies by influencing their distribution clearance and pharmacokinetics, explaining their variable effectiveness, is also addressed. Finally, the very promising effect of monoclonal antibodies that inhibit FcRn, suc",
      "strength": "medium"
    },
    {
      "pmid": "40020261",
      "year": "2025",
      "claim": "A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity.",
      "source": "EBioMedicine",
      "abstract": "BACKGROUND: Despite the importance of vaccination- and infection-elicited antibodies (Abs) to SARS-CoV-2 immunity, current mouse models do not fully capture the dynamics of Ab-mediated immunity in vivo, including potential contributions of the neonatal Fc receptor, encoded by FCGRT. METHODS: We generated triple knock-in (TKI) mice expressing human ACE2, TMPRSS2, and FCGRT; and evaluated the protective efficacy of anti-SARS-CoV-2 monoclonal Abs (mAbs) and plasma from individuals with immunity elicited by vaccination alone plus SARS-CoV-2 infection-induced (hybrid) immunity. FINDINGS: A human anti-SARS-CoV-2 mAb harbouring a half-life-extending mutation, but not the wild-type mAb, exhibited prolonged half-life in TKI mice and protected against lung infection with Omicron BA.2, validating the utility of these mice for evaluating therapeutic Abs. Pooled plasma from individuals with hybrid immunity to Delta, but not from vaccinated-only individuals, cleared infectious Delta from the lungs of TKI mice (P < 0.01), even though the two plasma pools had similar Delta-binding and -neutralising Ab titres in vitro. Similarly, plasma from individuals with hybrid Omicron BA.1/2 immunity, but not hybrid Delta immunity, decreased lung infection (P < 0.05) with BA.5 in TKI mice, despite the plasma pools having comparable BA.5-binding and -neutralising titres in vitro. Depletion of receptor-binding domain-targeting Abs from hybrid immune plasma abrogated their protection against infection. INTE",
      "strength": "medium"
    },
    {
      "pmid": "33025844",
      "year": "2020",
      "claim": "Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human FCGRT transgenic mice.",
      "source": "MAbs",
      "abstract": "A major asset of many monoclonal antibody (mAb)-based biologics is their persistence in circulation. The MHC class I family Fc receptor, FCGRT, is primarily responsible for this extended pharmacokinetic behavior. Engagement of FCGRT with the crystallizable fragment (Fc) domain protects IgG from catabolic elimination, thereby extending the persistence and bioavailability of IgG and related Fc-based biologics. There is a need for reliable in vivo models to facilitate the preclinical development of novel IgG-based biologics. FcRn-humanized mice have been widely accepted as translationally relevant surrogates for IgG-based biologics evaluations. Although such FCGRT-humanized mice, especially the mouse strain, B6.Cg-Fcgrttm1Dcr Tg(FCGRT)32Dcr (abbreviated Tg32), have been substantially validated for modeling humanized IgG-based biologics, there is a recognized caveat - they lack an endogenous source of human IgG that typifies the human competitive condition. Here, we used CRISPR/Cas9-mediated homology-directed repair to equip the hFCGRT Tg32 strain with a human IGHG1 Fc domain. This replacement now results in mice that produce human IgG1 Fc-mouse IgG Fab2 chimeric antibodies at physiologically relevant levels, which can be further heightened by immunization. This endogenous chimeric IgG1 significantly dampens the serum half-life of administered humanized mAbs in an hFCGRT-dependent manner. Thus, such IgG1-Fc humanized mice may provide a more physiologically relevant competitive hF",
      "strength": "medium"
    },
    {
      "pmid": "20930418",
      "year": "2010",
      "claim": "Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis.",
      "source": "Drug Metab Pharmacokinet",
      "abstract": "Neonatal Fc receptor (FcRn) plays an important role in regulating IgG homeostasis in the body. Changes in FcRn expression levels or activity caused by genetic polymorphisms of FCGRT, which encodes FcRn, may lead to interindividual differences in pharmacokinetics of therapeutic antibodies. In this study, we sequenced the 5'-flanking region, all exons and their flanking regions of FCGRT from 126 Japanese subjects. Thirty-three genetic variations, including 17 novel ones, were found. Of these, two novel non-synonymous variations, 629G>A (R210Q) and 889T>A (S297T), were found as heterozygous variations. We next assessed the functional significance of the two novel non-synonymous variations by expressing wild-type and variant proteins in HeLa cells. Both variant proteins showed similar intracellular localization as well as antibody recycling efficiencies. These results suggested that at least no common functional polymorphic site with amino acid change was present in the FCGRT of our Japanese population.",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "28785825",
      "year": "2018",
      "claim": "Functional polymorphisms in rhesus macaque FCGRT and β2-m.",
      "source": "Immunogenetics",
      "abstract": "Rhesus macaque is an important animal model for studies testing interventions like antibody therapeutics; as such knowledge of inter-individual variations in function of genes affecting antibody recycling is important for optimal experimental design. Neonatal Fc receptor (FcRn), a heterodimer composed of FCGRT and β2-m chains, plays critical role in extending catabolic half-life of IgG. We studied genomic polymorphisms in rhesus macaque FcRn and asked if they are functional by assessing correlations with serum IgG or β2-m levels. We tested 75 animals and report the presence of a VNTR polymorphism in promoter of FcRn as well as a single nucleotide polymorphism in the signal peptide of β2-m. A VNTR minor allele was associated with lower levels of serum IgG. This polymorphism may account for inter-animal variation in antibody levels and has relevance for effective design of rhesus macaque studies investigating vaccine-induced antibody responses and passive immunizations.",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "40715281",
      "year": "2025",
      "claim": "Advanced human FcRn knock-in mice for pharmacokinetic profiling of therapeutic antibodies.",
      "source": "Sci Rep",
      "abstract": "IgG-based therapeutic antibodies are increasingly adopted for diverse human diseases, such as cancer and autoimmune disorders displaying remarkable therapeutic performance. A key factor in their success lies in the extended half-life of IgG molecules, which is regulated by the pH-dependent interaction between IgG and neonatal Fc receptor (FcRn). This interaction prevents lysosomal degradation of IgG. Despite the frequent use of humanized rodent models expressing human FcRn (hFcRn) in preclinical studies, these models often fail to accurately replicate human antibody pharmacokinetics (PK) due to the use of non-native promoters that influence FcRn expression. To overcome this limitation, we developed an innovative humanized FcRn knock-in (hiFcRn) mouse model using CRISPR/Cas9 technology. This model integrates hFcRn cDNA into the endogenous locus of the mouse Fcgrt gene, completely replacing native mouse FcRn (mFcRn) expression. The hiFcRn mouse model offers a more human-relevant platform for the preclinical evaluation of therapeutic antibodies and Fc-fusion proteins.",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "37932271",
      "year": "2023",
      "claim": "An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission",
      "source": "Nat Commun",
      "abstract": "SARS-CoV-2 is primarily transmitted through droplets and airborne aerosols, and in order to prevent infection and reduce viral spread vaccines should elicit protective immunity in the airways. The neonatal Fc receptor (FcRn) transfers IgG across epithelial barriers and can enhance mucosal delivery of antigens. Here we explore FcRn-mediated respiratory delivery of SARS-CoV-2 spike (S). A monomeric IgG Fc was fused to a stabilized spike; the resulting S-Fc bound to S-specific antibodies and FcRn. Intranasal immunization of mice with S-Fc and CpG significantly induced antibody responses compared to the vaccination with S alone or PBS. Furthermore, we intranasally immunized mice or hamsters with S-Fc. A significant reduction of virus replication in nasal turbinate, lung, and brain was observed following nasal challenges with SARS-CoV-2 and its variants. Intranasal immunization also significantly reduced viral airborne transmission in hamsters. Nasal IgA, neutralizing antibodies, lung-resident memory T cells, and bone-marrow S-specific plasma cells mediated protection. Hence, FcRn delivers an S-Fc antigen effectively into the airway and induces protection against SARS-CoV-2 infection and transmission.",
      "strength": "strong"
    },
    {
      "pmid": "41031862",
      "year": "2025",
      "claim": "Antibody Engineering for Receptor-Mediated Transcytosis Across the Blood-Brain Barrier",
      "source": "Bioconjug Chem",
      "abstract": "Efficient delivery of therapeutic antibodies into the central nervous system (CNS) remains severely limited by the restrictive nature of the blood-brain barrier (BBB). Receptor-mediated transcytosis (RMT) has emerged as a promising strategy to enhance antibody transport across the BBB. In this Viewpoint, we highlight recent advances in RMT-based antibody delivery, focusing specifically on three representative BBB receptors: transferrin receptor (TfR), insulin receptor (InsR), and neonatal Fc receptor (FcRn). By comparing antibody engineering strategies that target these receptors, we summarize current progress, discuss critical limitations, and suggest directions for advancing CNS-targeted therapeutic antibodies. This Viewpoint provides valuable insights for selecting appropriate RMT targets and optimizing antibody-based therapies for CNS diseases.",
      "strength": "strong"
    },
    {
      "pmid": "41755010",
      "year": "2026",
      "claim": "Impact of Neonatal Fc Receptor on Transferrin Receptor Antibody Fusion Protein Pharmacokinetics",
      "source": "Pharmaceutics",
      "abstract": "Background: Transferrin receptor-targeting monoclonal antibodies (TfRMAbs) enhance brain drug delivery by facilitating TfR-mediated transcytosis across the blood-brain barrier (BBB). Data suggest that chronic TfRMAb dosing reduces their plasma exposure in a dose- and fusion partner-dependent manner; however, the underlying mechanisms remain unclear. The neonatal Fc receptor (FcRn) extends IgG half-life via recycling, but its saturation after repeated doses may alter the pharmacokinetics (PK) of IgG fusion proteins. This study evaluated the role of the FcRn on the PK and biodistribution of TfRMAb fusion proteins. Methods: We examined TfRMAb alone and TfRMAb fused to erythropoietin (TfRMAb-EPO) or TNFα receptor (TfRMAb-TNFR) in wild-type (WT) and FcRn knockout (KO) mice following acute (single dose) or chronic (3× weekly for 4 weeks) subcutaneous administration at 3 mg/kg. Plasma levels, tissue biodistribution, and FcRn binding were measured using immunoassays. Results: Our results show that fusion partners influenced FcRn-mediated recycling and PK of TfRMAb fusion proteins. After acute dosing, TfRMAb-TNFR exhibited the greatest reduction in plasma exposure in FcRn KO versus WT mice, compared with TfRMAb and TfRMAb-EPO. Chronic dosing reduced the plasma persistence of all fusion proteins in WT mice. In FcRn KO mice, plasma exposure of TfRMAb and TfRMAb-EPO decreased with chronic dosing, whereas TfRMAb-TNFR showed no further reduction. Differences in FcRn binding affinity likely",
      "strength": "strong"
    },
    {
      "pmid": "23978455",
      "year": "2013",
      "claim": "Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn",
      "source": "Brain Res",
      "abstract": "Monoclonal antibody (mAb) engineering that optimizes binding to receptors present on brain vascular endothelial cells has enabled them to cross through the blood-brain barrier (BBB) and access the brain parenchyma to treat neurological diseases. However, once in the brain the extent to which receptor-mediated reverse transcytosis clears mAb from the brain is unknown. The aim of this study was to determine the contribution of the neonatal Fc-receptor (FcRn) in rat brain efflux employing two different in vivo drug delivery models. Two mAb variants with substantially different affinities to FcRn, and no known neuronal targets, (IgG1 N434A and H435A) were administered to rats via intranasal-to-central nervous system (CNS) and intra-cranial dosing techniques. Levels of full-length IgG were quantified in serum and brain hemispheres by a sensitive enzyme-linked immunosorbent assay (ELISA). Following intra-nasal delivery, low cerebral hemisphere levels of variants were obtained at 20min, with a trend towards faster clearance of the high FcRn binder (N434A); however, the relatively higher serum levels confounded analysis of brain FcRn contribution to efflux. Using stereotaxic coordinates, we optimized the timing and dosing regimen for injection of mAb into the cortex. Levels of N434A, but not H435A, decreased in the cerebral hemispheres following bilateral injection into the rat cortex and higher levels of N434A were detected in serum compared to H435A after 24h. Immunohistochemical s",
      "strength": "strong"
    },
    {
      "pmid": "32461332",
      "year": "2020",
      "claim": "Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys",
      "source": "Sci Transl Med",
      "abstract": "Effective delivery of protein therapeutics to the central nervous system (CNS) has been greatly restricted by the blood-brain barrier (BBB). We describe the development of a BBB transport vehicle (TV) comprising an engineered Fc fragment that exploits receptor-mediated transcytosis for CNS delivery of biotherapeutics by binding a highly expressed brain endothelial cell target. TVs were engineered using directed evolution to bind the apical domain of the human transferrin receptor (hTfR) without the use of amino acid insertions, deletions, or unnatural appendages. A crystal structure of the TV-TfR complex revealed the TV binding site to be away from transferrin and FcRn binding sites, which was further confirmed experimentally in vitro and in vivo. Recombinant expression of TVs fused to anti-β-secretase (BACE1) Fabs yielded antibody transport vehicle (ATV) molecules with native immunoglobulin G (IgG) structure and stability. Peripheral administration of anti-BACE1 ATVs to hTfR-engineered mice and cynomolgus monkeys resulted in substantially improved CNS uptake and sustained pharmacodynamic responses. The TV platform readily accommodates numerous additional configurations, including bispecific antibodies and protein fusions, yielding a highly modular CNS delivery platform.",
      "strength": "strong"
    },
    {
      "pmid": "21613623",
      "year": "2011",
      "claim": "Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target",
      "source": "Sci Transl Med",
      "abstract": "Monoclonal antibodies have therapeutic potential for treating diseases of the central nervous system, but their accumulation in the brain is limited by the blood-brain barrier (BBB). Here, we show that reducing the affinity of an antibody for the transferrin receptor (TfR) enhances receptor-mediated transcytosis of the anti-TfR antibody across the BBB into the mouse brain where it reaches therapeutically relevant concentrations. Anti-TfR antibodies that bind with high affinity to TfR remain associated with the BBB, whereas lower-affinity anti-TfR antibody variants are released from the BBB into the brain and show a broad distribution 24 hours after dosing. We designed a bispecific antibody that binds with low affinity to TfR and with high affinity to the enzyme β-secretase (BACE1), which processes amyloid precursor protein into amyloid-β (Aβ) peptides including those associated with Alzheimer's disease. Compared to monospecific anti-BACE1 antibody, the bispecific antibody accumulated in the mouse brain and led to a greater reduction in brain Aβ after a single systemic dose. TfR-facilitated transcytosis of this bispecific antibody across the BBB may enhance its potency as an anti-BACE1 therapy for treating Alzheimer's disease.",
      "strength": "strong"
    },
    {
      "pmid": "39715817",
      "year": "2024",
      "claim": "A shorter linker in the bispecific antibody RmAb158-scFv8D3 improves TfR-mediated blood-brain barrier transcytosis in vitro",
      "source": "Sci Rep",
      "abstract": "Transferrin Receptor (TfR)-mediated transcytosis across the blood-brain barrier (BBB) enables the uptake of bispecific therapeutic antibodies into the brain. At therapeutically relevant concentrations, bivalent binding to TfR appears to reduce the transcytosis efficiency by receptor crosslinking. In this study, we aimed to improve BBB transcytosis of symmetric antibodies through minimizing their ability to cause TfR crosslinking. We created variants of the previously published RmAb158-scFv8D3, where the linker length between RmAb158 and the mTfR-targeting scFv8D3 was adjusted. We investigated the effect of the linker length on the antibodies' binding kinetics to mTfR using ELISA and LigandTracer assays, and their ability to transcytose across BBB endothelial cells (In-Cell BBB-Trans assay). We show that even a direct fusion without a linker does not alter the antibodies' apparent affinities to mTfR indicating their valency is unlikely affected by the linker length. However, the shortest linker variants demonstrated BBB transcytosis levels comparable to that of the monovalent control at a high antibody concentration and showed an almost two-fold higher level of BBB transcytosis compared to the longer-linker variants at the high concentration. Our new RmAb158-scFv8D3 short-linker variants are examples of symmetric, therapeutic antibodies with improved TfR-binding characteristics to facilitate more efficient brain uptake. We hypothesize that bivalent binding to TfR as such does ",
      "strength": "strong"
    },
    {
      "pmid": "40425446",
      "year": "2025",
      "claim": "Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease",
      "source": "J Prev Alzheimers Dis",
      "abstract": "The emerging class of bispecific antibodies represents a significant advancement in Alzheimer's disease (AD) immunotherapy by addressing the limited brain concentrations achieved with conventional monoclonal antibodies. The majority of bispecific antibodies developed for AD treatment utilize transferrin receptor (TfR1)-mediated transcytosis to enhance blood-brain barrier (BBB) penetration, resulting in higher and more uniform brain concentrations compared to conventional antibodies. This improved delivery has demonstrated superior efficacy in reducing brain amyloid-beta (Aβ) burden. Additionally, TfR1-mediated delivery may help mitigate adverse effects such as amyloid-related imaging abnormalities (ARIA). This is likely achieved by a reduction in antibody accumulation at vascular Aβ deposits, resulting from the combined effects of lower dosing and a different brain entry route when using bispecific antibodies. Besides targeting Aβ, bispecific antibodies have been engineered to address other key pathological features of AD, including tau pathology and neuroinflammatory targets, which are critical drivers of disease progression. These antibodies also show promise in diagnostic applications, particularly as radioligands for antibody-based positron emission tomography (immunoPET), leveraging their rapid brain delivery and efficient and specific target engagement. Moreover, the principles of bispecific antibody technology have been adapted for use beyond immunotherapy. The incorpo",
      "strength": "strong"
    },
    {
      "pmid": "36077002",
      "year": "2022",
      "claim": "Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review",
      "source": "Int J Mol Sci",
      "abstract": "Understanding the biological mechanisms underlying the pH-dependent nature of FcRn binding, as well as the various factors influencing the affinity to FcRn, was concurrent with the arrival of the first recombinant IgG monoclonal antibodies (mAbs) and IgG Fc-fusion proteins in clinical practice. IgG Fc-FcRn became a central subject of interest for the development of these drugs for the comfort of patients and good clinical responses. In this review, we describe (i) mAb mutations close to and outside the FcRn binding site, increasing the affinity for FcRn at acidic pH and leading to enhanced mAb half-life and biodistribution, and (ii) mAb mutations increasing the affinity for FcRn at acidic and neutral pH, blocking FcRn binding and resulting, in vivo, in endogenous IgG degradation. Mutations modifying FcRn binding are discussed in association with pH-dependent modulation of antigen binding and (iii) anti-FcRn mAbs, two of the latest innovations in anti-FcRn mAbs leading to endogenous IgG depletion. We discuss the pharmacological effects, the biological consequences, and advantages of targeting IgG-FcRn interactions and their application in human therapeutics.",
      "strength": "strong"
    },
    {
      "pmid": "16186811",
      "year": "2005",
      "claim": "Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels",
      "source": "Nat Biotechnol",
      "abstract": "We have engineered the Fc region of a human immunoglobulin G (IgG) to generate a mutated antibody that modulates the concentrations of endogenous IgGs in vivo. This has been achieved by targeting the activity of the Fc receptor, FcRn, which serves through its IgG salvage function to maintain and regulate IgG concentrations in the body. We show that an IgG whose Fc region was engineered to bind with higher affinity and reduced pH dependence to FcRn potently inhibits FcRn-IgG interactions and induces a rapid decrease of IgG levels in mice. Such FcRn blockers (or 'Abdegs,' for antibodies that enhance IgG degradation) may have uses in reducing IgG levels in antibody-mediated diseases and in inducing the rapid clearance of IgG-toxin or IgG-drug complexes.",
      "strength": "strong"
    },
    {
      "pmid": "25658443",
      "year": "2015",
      "claim": "The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity",
      "source": "MAbs",
      "abstract": "The neonatal Fc receptor (FcRn) is expressed by cells of epithelial, endothelial and myeloid lineages and performs multiple roles in adaptive immunity. Characterizing the FcRn/IgG interaction is fundamental to designing therapeutic antibodies because IgGs with moderately increased binding affinities for FcRn exhibit superior serum half-lives and efficacy. It has been hypothesized that 2 FcRn molecules bind an IgG homodimer with disparate affinities, yet their affinity constants are inconsistent across the literature. Using surface plasmon resonance biosensor assays that eliminated confounding experimental artifacts, we present data supporting an alternate hypothesis: 2 FcRn molecules saturate an IgG homodimer with identical affinities at independent sites, consistent with the symmetrical arrangement of the FcRn/Fc complex observed in the crystal structure published by Burmeister et al. in 1994. We find that human FcRn binds human IgG1 with an equilibrium dissociation constant (KD) of 760 ± 60 nM (N = 14) at 25°C and pH 5.8, and shows less than 25% variation across the other human subtypes. Human IgG1 binds cynomolgus monkey FcRn with a 2-fold higher affinity than human FcRn, and binds both mouse and rat FcRn with a 10-fold higher affinity than human FcRn. FcRn/IgG interactions from multiple species show less than a 2-fold weaker affinity at 37°C than at 25°C and appear independent of an IgG's variable region. Our in vivo data in mouse and rat models demonstrate that both affi",
      "strength": "strong"
    },
    {
      "pmid": "26864109",
      "year": "2016",
      "claim": "Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation",
      "source": "Immunol Rev",
      "abstract": "Monoclonal antibodies have become a general modality in therapeutic development, and a variety of monoclonal antibodies targeting soluble antigens have been developed. However, even with infinite binding affinity to an antigen, a conventional antibody can bind to the antigen only once and results in an increase in total plasma antigen concentration in vivo. This antibody-mediated antigen accumulation generally occurs because the clearance from circulation of an antibody-antigen complex is much slower than that of a free antigen. This limitation has recently been overcome by sweeping antibodies, which are capable of actively eliminating soluble antigens from circulation. A sweeping antibody incorporates two antibody engineering technologies: one is variable region engineering to enable the antibody to bind to an antigen in plasma and dissociate from the antigen in endosome (after which the antigen undergoes lysosomal degradation), and the other is constant region engineering to increase the cellular uptake of the antibody-antigen complex into endosome. By enhancing the elimination of soluble antigens from circulation, sweeping antibodies can therapeutically target soluble antigens that conventional antibodies cannot. This review discusses the features, engineering technologies, advantages, and applications of sweeping antibodies that target soluble antigens.",
      "strength": "strong"
    },
    {
      "pmid": "41338456",
      "year": "2026",
      "claim": "A humanized transferrin receptor 1-transferrin model supports functional iron homeostasis and therapeutic delivery across the blood-brain barrier",
      "source": "J Biol Chem",
      "abstract": "The transferrin receptor 1 (TfR1)-transferrin (TF) axis is central to iron homeostasis and represents a validated route for delivering biologics across the blood-brain barrier (BBB). We developed human-specific anti-TfR1 nanobodies (NewroBus) that exploit this pathway, but their lack of cross-reactivity with rodent TfR1 limits conventional preclinical testing. To overcome this, we generated knock-in rats in which the coding sequences of the endogenous Tfrc and Tf genes were replaced with their human counterparts, producing animals that express human TfR1 and/or human TF under physiological control. Rats homozygous for both humanized alleles were viable and fertile, indicating functional replacement of their rodent orthologs but exhibited erythropoietic abnormalities and altered iron distribution-reduced splenic and increased hepatic iron-suggesting incomplete compensation. In contrast, heterozygous rats displayed only mild, subclinical microcytosis and hypochromia while maintaining normal BBB integrity and near-physiological iron homeostasis. Using these heterozygous humanized Tfrc rats, we demonstrated that a biologic engineered to engage human TfR1, NewroBus, fused to a therapeutic payload such as TNFα-neutralizing nanobodies, achieved significant BBB penetration and central nervous system exposure. These results validate the translational relevance of this model for studying TfR1-mediated drug delivery. Overall, the humanized TfR1-TF axis is compatible with life and system",
      "strength": "strong"
    },
    {
      "pmid": "35890374",
      "year": "2022",
      "claim": "IgG Fusion Proteins for Brain Delivery of Biologics via Blood-Brain Barrier Receptor-Mediated Transport",
      "source": "Pharmaceutics",
      "abstract": "The treatment of neurological disorders with large-molecule biotherapeutics requires that the therapeutic drug be transported across the blood-brain barrier (BBB). However, recombinant biotherapeutics, such as neurotrophins, enzymes, decoy receptors, and monoclonal antibodies (MAb), do not cross the BBB. These biotherapeutics can be re-engineered as brain-penetrating bifunctional IgG fusion proteins. These recombinant proteins comprise two domains, the transport domain and the therapeutic domain, respectively. The transport domain is an MAb that acts as a molecular Trojan horse by targeting a BBB-specific endogenous receptor that induces receptor-mediated transcytosis into the brain, such as the human insulin receptor (HIR) or the transferrin receptor (TfR). The therapeutic domain of the IgG fusion protein exerts its pharmacological effect in the brain once across the BBB. A generation of bifunctional IgG fusion proteins has been engineered using genetically engineered MAbs directed to either the BBB HIR or TfR as the transport domain. These IgG fusion proteins were validated in animal models of lysosomal storage disorders; acute brain conditions, such as stroke; or chronic neurodegeneration, such as Parkinson's disease and Alzheimer's disease. Human phase I-III clinical trials were also completed for Hurler MPSI and Hunter MPSII using brain-penetrating IgG-iduronidase and -iduronate-2-sulfatase fusion protein, respectively.",
      "strength": "strong"
    },
    {
      "pmid": "31342134",
      "year": "2019",
      "claim": "Engineered antibodies: new possibilities for brain PET?",
      "source": "Eur J Nucl Med Mol Imaging",
      "abstract": "Almost 50 million people worldwide are affected by Alzheimer's disease (AD), the most common neurodegenerative disorder. Development of disease-modifying therapies would benefit from reliable, non-invasive positron emission tomography (PET) biomarkers for early diagnosis, monitoring of disease progression, and assessment of therapeutic effects. Traditionally, PET ligands have been based on small molecules that, with the right properties, can penetrate the blood-brain barrier (BBB) and visualize targets in the brain. Recently a new class of PET ligands based on antibodies have emerged, mainly in applications related to cancer. While antibodies have advantages such as high specificity and affinity, their passage across the BBB is limited. Thus, to be used as brain PET ligands, antibodies need to be modified for active transport into the brain. Here, we review the development of radioligands based on antibodies for visualization of intrabrain targets. We focus on antibodies modified into a bispecific format, with the capacity to undergo transferrin receptor 1 (TfR1)-mediated transcytosis to enter the brain and access pathological proteins, e.g. amyloid-beta. A number of such antibody ligands have been developed, displaying differences in brain uptake, pharmacokinetics, and ability to bind and visualize the target in the brain of transgenic mice. Potential pathological changes related to neurodegeneration, e.g. misfolded proteins and neuroinflammation, are suggested as future tar",
      "strength": "strong"
    },
    {
      "pmid": "39676023",
      "year": "2025",
      "claim": "A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology",
      "source": "Neurotherapeutics",
      "abstract": "Parkinson's disease (PD) is characterized by a progressive loss of dopaminergic neurons, linked to aggregation of alpha-synuclein (αSYN) into Lewy bodies. Current treatments are symptomatic and do not halt or reverse the neurodegeneration. Immunotherapy targeting aggregated αSYN shows potential, but therapeutic efficacy is limited by poor brain penetration of antibodies. We developed a bispecific antibody, RmAb38E2-scFv8D3, based on αSYN oligomer selective RmAb38E2 fused to a transferrin receptor (TfR)-binding domain to enhance brain delivery. Both RmAb38E2 and RmAb38E2-scFv8D3 showed higher affinity for αSYN oligomers than for monomers or fibrils. In vivo, RmAb38E2-scFv8D3 exhibited higher brain and lower blood concentrations compared to RmAb38E2, suggesting a better brain uptake and reduced peripheral exposure for the bispecific antibody. Treatment over five days of 3-4 months old transgenic L61 mice, which overexpress human αSYN, with three doses of RmAb38E2-scFv8D3 reduced brain αSYN oligomer levels and increased microglial activation, as indicated by elevated soluble TREM2 levels. Treatment with the monospecific RmAb38E2, however, showed no significant effect compared to PBS. This study demonstrates that TfR-mediated delivery enhances the therapeutic potential of αSYN-targeted immunotherapy by resulting in a higher concentration and a more uniform distribution of antibodies in the brain. The use of bispecific antibodies offers a promising strategy to improve the efficacy",
      "strength": "strong"
    },
    {
      "pmid": "38007619",
      "year": "2023",
      "claim": "Strategies to identify, engineer, and validate antibodies targeting blood-brain barrier receptor-mediated transcytosis systems for CNS drug delivery",
      "source": "Expert Opin Drug Deliv",
      "abstract": "INTRODUCTION: Numerous therapeutics for neurological diseases have been developed, but many have failed in clinical trials in part due to limited brain bioavailability, mainly stemming from inefficient transport through the blood-brain barrier (BBB). One potential approach to noninvasive, BBB-targeted drug delivery to the brain is the use of engineered antibodies as delivery vehicles that can transport conjugated drug cargo across the BBB and into the brain via receptor-mediated transcytosis (RMT). Effective development of these RMT targeting systems includes novel target discovery, along with antibody engineering and subsequent validation. AREAS COVERED: This review focuses on both known and emerging RMT systems, targeting antibody properties in relation to BBB trafficking, and antibody validation strategies. EXPERT OPINION: Clinical development of known RMT targeting systems and identification of novel BBB RMT targets will be complementary strategies for overcoming the BBB in central nervous system (CNS) disease treatment. The search for new RMT targets with higher brain specificity and enriched expression in the brain has given rise to some new targets which may offer unique benefits. It is our opinion that the expansion of BBB RMT system identification, along with targeting molecule engineering and validation strategies, will substantially contribute to the treatment of a wide range of neurological diseases.",
      "strength": "strong"
    },
    {
      "pmid": "36346674",
      "year": "2022",
      "claim": "Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy",
      "source": "JCI Insight",
      "abstract": "Antisense oligonucleotides (ASOs) have emerged as one of the most innovative new genetic drug modalities. However, their high molecular weight limits their bioavailability for otherwise-treatable neurological disorders. We investigated conjugation of ASOs to an antibody against the murine transferrin receptor, 8D3130, and evaluated it via systemic administration in mouse models of the neurodegenerative disease spinal muscular atrophy (SMA). SMA, like several other neurological and neuromuscular diseases, is treatable with single-stranded ASOs that modulate splicing of the survival motor neuron 2 (SMN2) gene. Administration of 8D3130-ASO conjugate resulted in elevated levels of bioavailability to the brain. Additionally, 8D3130-ASO yielded therapeutic levels of SMN2 splicing in the central nervous system of adult human SMN2-transgenic (hSMN2-transgenic) mice, which resulted in extended survival of a severely affected SMA mouse model. Systemic delivery of nucleic acid therapies with brain-targeting antibodies offers powerful translational potential for future treatments of neuromuscular and neurodegenerative diseases.",
      "strength": "strong"
    },
    {
      "pmid": "38494152",
      "year": "2024",
      "claim": "RNA therapies for CNS diseases",
      "source": "Adv Drug Deliv Rev",
      "abstract": "Neurological disorders are a diverse group of conditions that pose an increasing health burden worldwide. There is a general lack of effective therapies due to multiple reasons, of which a key obstacle is the presence of the blood-brain barrier, which limits drug delivery to the central nervous system, and generally restricts the pool of candidate drugs to small, lipophilic molecules. However, in many cases, these are unable to target key pathways in the pathogenesis of neurological disorders. As a group, RNA therapies have shown tremendous promise in treating various conditions because they offer unique opportunities for specific targeting by leveraging Watson-Crick base pairing systems, opening up possibilities to modulate pathological mechanisms that previously could not be addressed by small molecules or antibody-protein interactions. This potential paradigm shift in disease management has been enabled by recent advances in synthesizing, purifying, and delivering RNA. This review explores the use of RNA-based therapies specifically for central nervous system disorders, where we highlight the inherent limitations of RNA therapy and present strategies to augment the effectiveness of RNA therapeutics, including physical, chemical, and biological methods. We then describe translational challenges to the widespread use of RNA therapies and close with a consideration of future prospects in this field.",
      "strength": "strong"
    },
    {
      "pmid": "41110474",
      "year": "2025",
      "claim": "Novel single-domain antibodies targeting a unique transferrin receptor 1 epitope for cross-species delivery of drugs in the central nervous system",
      "source": "J Control Release",
      "abstract": "The blood-brain barrier (BBB) is a major obstacle for delivering therapeutic agents to the central nervous system (CNS), posing significant challenges for treating neurological disorders. Among current strategies to improve brain drug exposure, hijacking physiological pathways involved in receptor-mediated transcytosis has emerged as a promising strategy. While targeting transferrin receptor 1 (TfR1) is widely explored, many TfR1- antibodies lack cross-species reactivity, limiting translational development. In the present study, we identified and characterized camelid-derived single-domain antibodies (VHHs) with robust cross-reactivity to rodent, rhesus monkey, and human TfR1. Epitope mapping of the VHH revealed a novel binding site at the interface of the TfR1 dimer. When fused to a human IgG1 Fc domain, these VHHs, as monomers or homodimers, were efficiently internalized by engineered CHO cells and brain endothelial cells expressing TfR1 from different species. Systemic administration of VHH-Fc constructs in mice demonstrated significantly improved brain uptake compared to irrelevant controls. Functional delivery was confirmed using neurotensin-induced hypothermia, and we established correlations between in vivo effects and binding properties determined by surface plasmon resonance. Notably, efficient BBB transcytosis was associated with intermediate affinity and rapid dissociation rates. Engineered variants maintained favorable cross-species binding, including similar affi",
      "strength": "strong"
    }
  ],
  "evidence_against": [
    {
      "pmid": "40533746",
      "year": "2025",
      "claim": "Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges",
      "source": "J Nanobiotechnology",
      "abstract": "Recent advancements in gene expression modulation and RNA delivery systems have underscored the immense potential of nucleic acid-based therapies (NA-BTs) in biological research. However, the blood-brain barrier (BBB), a crucial regulatory structure that safeguards brain function, presents a significant obstacle to the delivery of drugs to glial cells and neurons. The BBB tightly regulates the movement of substances from the bloodstream into the brain, permitting only small molecules to pass through. This selective permeability poses a significant challenge for effective therapeutic delivery, especially in the case of NA-BTs. Extracellular vesicles, particularly exosomes, are recognized as valuable reservoirs of potential biomarkers and therapeutic targets. They are also gaining significant attention as innovative drug and nucleic acid delivery (NAD) carriers. Their unique ability to safeguard and transport genetic material, inherent biocompatibility, and capacity to traverse physiological barriers highlight their potential as drug carriers. This review provides a comprehensive overview of current strategies to enhance NAD to the brain, focusing on the emerging potential of exosomes as biocompatible and efficient nanocarriers. It synthesizes recent advances in the use of exosomes for NA-BTs in neurological disorders, comparing their advantages with those of conventional nanodelivery systems and cell-based therapies. Additionally, the review highlights innovative exosome engin",
      "strength": "medium"
    },
    {
      "pmid": "41199078",
      "year": "2025",
      "claim": "Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next-Generation Therapies",
      "source": "Pharm Res",
      "abstract": "The convergence of peptides and nanoparticles through bionanoconjugation has emerged as a transformative strategy to address the persistent challenges in treating neurodegenerative disorders. Peptides, particularly short sequences (< 45 amino acids), offer unique advantages as protein mimetics, including structural flexibility, target specificity and blood-brain barrier permeability. Their clinical translation is hindered by rapid enzymatic degradation, short half-life, and poor bioavailability. Conjugation with nanoparticles, overcomes these limitations by enhancing stability, prolonging circulation, and enabling precise targeting. Peptide-nanoparticle conjugates, including TAT-functionalized gold nanoparticles and RGD-decorated polymeric systems, have shown significant improvements in blood brain barrier penetration. These advancements are associated with a reduction in amyloid-beta aggregation and the inhibition of tau hyperphosphorylation in preclinical models. These hybrids leverage peptides dual roles as therapeutic agents and drug carriers, often exploiting receptor-mediated transport for brain delivery. This review critically evaluates covalent and noncovalent conjugation strategies, such as carbodiimide chemistry, ligand exchange, and click reactions, highlighting their impact on structural stability and bioactivity. We further discuss advances in peptide classes, including cell-penetrating peptides, nuclear localization signals, targeting peptides and bioactive pept",
      "strength": "medium"
    },
    {
      "pmid": "41197818",
      "year": "2026",
      "claim": "ROS-responsive nanogels for brain targeted delivery of icariin in the treatment of Parkinson's disease",
      "source": "Int J Pharm",
      "abstract": "Excessive reactive oxygen species (ROS)-induced nigrostriatal dopaminergic neuron degeneration is a cardinal pathological feature of Parkinson's disease (PD). Although icariin, a natural antioxidant capable of scavenging ROS, shows therapeutic potential, it remains underutilized in clinical settings. This translational gap primarily stems from two pharmacological limitations: (1) inadequate blood-brain barrier (BBB) penetration that prevents effective delivery of icariin to the brain, and (2) the lack of targeted drug release at pathological sites, thereby diminishing its local neuroprotective efficacy against ROS-mediated neurodegeneration. To overcome these challenges, we developed a ROS-responsive selenocysteamine-alginate nanogel (ASeNG-ICA) that bypasses the BBB via nose-to-brain delivery and enables pathology-triggered drug release through diselenide bond cleavage in the high-ROS microenvironments characteristic of PD. In vitro studies demonstrated that the nanogels undergo ROS-responsive disintegration, resulting in sustained icariin release under oxidative conditions. Following intranasal administration in mice, ASeNG-ICA achieved rapid brain biodistribution. In a PD mouse model, this delivery system significantly reduced striatal malondialdehyde (MDA) levels, regulated antioxidant enzymes (HO-1, SOD) expression, alleviated oxidative stress and improved behavioral disorders, surpassing conventional free icariin therapy. Overall, ASeNG-ICA resolves critical delivery ba",
      "strength": "medium"
    },
    {
      "pmid": "36257298",
      "year": "2022",
      "claim": "Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis",
      "source": "Med",
      "abstract": "BACKGROUND: The near impermeability of the blood-brain barrier (BBB) and the unique neuroimmune environment of the CNS prevents the effective use of antibodies in neurological diseases. Delivery of biotherapeutics to the brain can be enabled through receptor-mediated transcytosis via proteins such as the transferrin receptor, although limitations such as the ability to use Fc-mediated effector function to clear pathogenic targets can introduce safety liabilities. Hence, novel delivery approaches with alternative clearance mechanisms are warranted. METHODS: Binders that optimized transport across the BBB, known as transcytosis-enabling modules (TEMs), were identified using a combination of antibody discovery techniques and pharmacokinetic analyses. Functional activity of TEMs were subsequently evaluated by imaging for the ability of myeloid cells to phagocytose target proteins and cells. FINDINGS: We demonstrated significantly enhanced brain exposure of therapeutic antibodies using optimal transferrin receptor or CD98 TEMs. We found that these modules also mediated efficient clearance of tau aggregates and HER2+ tumor cells via a non-classical phagocytosis mechanism through direct engagement of myeloid cells. This mode of clearance potentially avoids the known drawbacks of FcγR-mediated antibody mechanisms in the brain such as the neurotoxic release of proinflammatory cytokines and immune cell exhaustion. CONCLUSIONS: Our study reports a new brain delivery platform that harnes",
      "strength": "medium"
    },
    {
      "pmid": "24411731",
      "year": "2014",
      "claim": "Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle",
      "source": "Neuron",
      "abstract": "Although biotherapeutics have vast potential for treating brain disorders, their use has been limited due to low exposure across the blood-brain barrier (BBB). We report that by manipulating the binding mode of an antibody fragment to the transferrin receptor (TfR), we have developed a Brain Shuttle module, which can be engineered into a standard therapeutic antibody for successful BBB transcytosis. Brain Shuttle version of an anti-Aβ antibody, which uses a monovalent binding mode to the TfR, increases β-Amyloid target engagement in a mouse model of Alzheimer's disease by 55-fold compared to the parent antibody. We provide in vitro and in vivo evidence that the monovalent binding mode facilitates transcellular transport, whereas a bivalent binding mode leads to lysosome sorting. Enhanced target engagement of the Brain Shuttle module translates into a significant improvement in amyloid reduction. These findings have major implications for the development of biologics-based treatment of brain disorders.",
      "strength": "medium"
    },
    {
      "pmid": "26687840",
      "year": "2016",
      "claim": "Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies",
      "source": "Neuron",
      "abstract": "The blood-brain barrier (BBB) poses a major challenge for developing effective antibody therapies for neurological diseases. Using transcriptomic and proteomic profiling, we searched for proteins in mouse brain endothelial cells (BECs) that could potentially be exploited to transport antibodies across the BBB. Due to their limited protein abundance, neither antibodies against literature-identified targets nor BBB-enriched proteins identified by microarray facilitated significant antibody brain uptake. Using proteomic analysis of isolated mouse BECs, we identified multiple highly expressed proteins, including basigin, Glut1, and CD98hc. Antibodies to each of these targets were significantly enriched in the brain after administration in vivo. In particular, antibodies against CD98hc showed robust accumulation in brain after systemic dosing, and a significant pharmacodynamic response as measured by brain Aβ reduction. The discovery of CD98hc as a robust receptor-mediated transcytosis pathway for antibody delivery to the brain expands the current approaches available for enhancing brain uptake of therapeutic antibodies.",
      "strength": "medium"
    },
    {
      "pmid": "35639288",
      "year": "2022",
      "claim": "Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals",
      "source": "Drugs",
      "abstract": "Myasthenia gravis (MG) is a chronic, fluctuating, antibody-mediated autoimmune disorder directed against the post-synaptic neuromuscular junctions of skeletal muscles, resulting in a wide spectrum of manifestations ranging from mild to potentially fatal. Given its unique natural course, designing an ideal trial design for MG has been wrought with difficulties and evidence in favour of several of the conventional agents is weak as per current standards. Despite this, acetylcholinesterases and corticosteroids have remained the cornerstones of treatment for several decades with intravenous immunoglobulins (IVIG) and therapeutic plasma exchange (PLEX) offering rapid treatment response, especially in crises. However, the treatment of MG entails long-term immunosuppression and conventional agents are viable options but take longer to act and have a number of class-specific adverse effects. Advances in immunology, translational medicine and drug development have seen the emergence of several newer biological agents which offer selective, target-specific immunotherapy with fewer side effects and rapid onset of action. Eculizumab is one of the newer agents that belong to the class of complement inhibitors and has been approved for the treatment of refractory general MG. Zilucoplan and ravulizumab are other agents in this group in clinical trials. Neisseria meningitis is a concern with all complement inhibitors, mandating vaccination. Neonatal Fc receptor (FcRn) inhibitors prevent immu",
      "strength": "medium"
    },
    {
      "pmid": "40807149",
      "year": "2025",
      "claim": "Redefining Treatment Paradigms in Thyroid Eye Disease: Current and Future Therapeutic Strategies",
      "source": "J Clin Med",
      "abstract": "Background: Thyroid eye disease (TED) is a rare autoimmune orbital disorder predominantly associated with Graves' disease. It is characterized by orbital inflammation, tissue remodeling, and potential visual morbidity. Conventional therapies, particularly systemic glucocorticoids, offer only partial symptomatic relief, failing to reverse chronic structural changes such as proptosis and diplopia, and are associated with substantial adverse effects. This review aims to synthesize recent developments in understandings of TED pathogenesis and to critically evaluate emerging therapeutic strategies. Methods: A systematic literature review was conducted using MEDLINE, Embase, and international clinical trial registries focusing on pivotal clinical trials and investigational therapies targeting core molecular pathways involved in TED. Results: Current evidence suggests that TED pathogenesis is primarily driven by the autoimmune activation of orbital fibroblasts (OFs) through thyrotropin receptor (TSH-R) and insulin-like growth factor-1 receptor (IGF-1R) signaling. Teprotumumab, a monoclonal IGF-1R inhibitor and the first therapy approved by the U.S. Food and Drug Administration for TED, has demonstrated substantial clinical benefit, including improvements in proptosis, diplopia, and quality of life. However, concerns remain regarding relapse rates and treatment-associated adverse events, particularly hearing impairment. Investigational therapies, including next-generation IGF-1R inhi",
      "strength": "medium"
    },
    {
      "pmid": "40403225",
      "year": "2025",
      "claim": "Development of a Novel Engineered Antibody Format for PSMA-Targeted Radionuclide Therapy",
      "source": "Mol Pharm",
      "abstract": "Prostate cancer remains a prevalent and lethal malignancy across the globe. Despite ongoing advances in therapeutic approaches, these remain ineffective, and new treatments are drastically needed. Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy is a well-developed approach for prostate cancer treatment; however, current small molecule and antibody carriers for molecular radiotherapy each have drawbacks in their biodistribution and consequent side effects as highlighted in current clinical trials. To address this, we developed an approach to bioengineer the well clinically validated antibody carrier HuJ591 to yield an engineered, full-length antibody construct that achieves the beneficial fast pharmacokinetic profile of small molecule carriers alongside the enhanced tumor targeting and reduced renal toxicity of antibody carriers. We report here a rational design process to produce a novel humanized PSMA-targeting antibody designed for the delivery of radiation with abrogated FcRn recycling that aims to reduce blood circulation time and minimize systemic exposure. We demonstrate that these IgG-based constructs retain the favorable properties of HuJ591, such as inherent protein stability, expression in systems compatible with industrial manufacture, and comparable, highly specific PSMA-binding characteristics. We then radiolabeled constructs with the diagnostic radionuclide 64Cu as a surrogate for therapeutic radionuclide payloads and undertook a proof-of",
      "strength": "medium"
    }
  ],
  "market_price": 0.7902
}